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Abstract:
Background:
Rheumatoid  arthritis  (RA)  is  a  systemic,  inflammatory  disease  that  affects  1% of  the  population.  The  auditory  system may  be
involved during the course of disease; however the association of RA and hearing impairment has not been clearly defined.
Objective:
The objective of this review is to evaluate published clinical reports related to hearing impairment in patients with RA. Furthermore,
we discuss possible pathologies and associated factors as well as new treatment modalities.
Method:
A thorough literature search was performed using available databases including Pubmed, Embase, Cochrane and ComDisDome to
cover  all  relative  reports.  The  following  keywords  were  used:  hearing  loss,  hearing  difficulties,  hearing  disorders,  hearing
impairment, sensorineural hearing loss, conductive hearing loss, mixed hearing loss, autoimmune hearing loss, drug ototoxicity,
drug-induced hearing loss, hearing test, audiometry, auditory dysfunction and rheumatoid arthritis.
Conclusion:
Based on our review it can be postulated that patients with RA are at higher risk of hearing impairment compared to healthy subjects
in their course of the disease. The hearing impairment in RA seems to be a multifactorial condition; however the mechanisms of
injury, as well as the relative risk factors, are not completely clear. This review can aid to clarify this condition and is a guide for
further evaluation. To the best of our knowledge, this is the first review of hearing impairment in RA.
Keywords: Audiometry, Conductive hearing loss, Hearing impairment, Hearing loss, Mixed hearing loss, Sensorineural hearing loss,
Rheumatoid Arthritis.
INTRODUCTION
Rheumatoid  arthritis  (RA)  is  a  chronic,  inflammatory  disease  that  affects  1% of  the  population  [1].  Despite  its
cardinal articular and periarticular features, RA can involve other organs including heart, lung, skin, and eye [2]. In the
same way, the auditory system can be affected by a variety of pathologies in the course of disease [3]. There is a wide
variation in the reported prevalence of different types of hearing loss in RA patients. Sensorineural hearing loss (SNHL)
is the most common type of hearing impairment in RA patients ranging from 25% to 72% [3]. Conductive hearing loss
(CHL) and mixed hearing loss (MHL) have also been reported less frequently [2, 4, 5]. The objective of this review is
to  discuss  recent  findings  on  the  pathology  and  associated  factors  of  hearing  impairment  in  RA  as  well  as  its
management.
* Address  correspondence  to this  author  at  the Department  of  Rheumatology,  Odense  University  Hospital,  Svendborg  Hospital,  Denmark;
Tel: +4551670948; Fax: +45 63202282; Email: amir.emamifar@rsyd.dk
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METHOD
A comprehensive search of Pubmed, Embase, Cochrane and ComDisDome databases was performed to cover all
relative  articles.  The  following  keywords  were  used:  hearing  loss,  hearing  difficulties,  hearing  disorders,  hearing
impairment, sensorineural hearing loss, conductive hearing loss, mixed hearing loss, autoimmune hearing loss, drug
ototoxicity, drug-induced hearing loss, hearing test, audiometry, auditory dysfunction, rheumatoid arthritis.
Fig. (1). Different pathologies of hearing impairment in Rheumatoid Arthritis. (Data were extracted from references 2, 4, 9-15, 20)
PATHOLOGY
A number of possible pathologies have been described by previous studies mainly as follows (Fig. 1):
Synovial destruction of incudostapedial (IS) and incudomalleolar (IM) joints by an inflammatory process. (Fig.1.
2) As IM and IS joints are true diarthroses, they may consequently be involved in RA, like any other joints in
the  body.  This  may  cause  no  clinical  symptoms  since  these  two  joints  are  functionally  fixed  during  sound
transmission [2, 4].
Rheumatoid nodules  are  the most  prevalent  extra-articular  manifestation in  RA patients  that  may present  in2.
different locations, however commonly found subcutaneously at points of pressure. Various ear nose throat sites
including  pharynx,  larynx  and  nose  as  well  as  the  ears  may  be  affected.  Treatment  with  methotrexate  and
possibly tumor necrosis factor (TNF) inhibitors may cause rheumatoid nodules or aggravate the tendency to
development [6 - 8].
Auditory neuropathy due to a probable vasculitis as a part of mononeuritis multiplex.3.
Destruction of the cochlear hair cells, or the inner ear due to immune complex deposition.4.
Drug-induced ototoxicity: Certain kind of drugs including salicylates, non-steroidal anti-inflammatory drugs5.
(NSAIDS),  antimalarial  and  some  other  disease-modifying  antirheumatic  drugs  (DMARDS)  can  affect  the
auditory system [4, 9 - 15].
Tinnitus, loss of absolute acoustic sensitivity and alterations of perceived sounds are the most frequent
side effects of large doses of salicylates. Symptoms develop shortly after treatment initiation, fluctuating
during the treatment, and are generally reversible [16].
Hydroxychloroquine  [17]  and  chloroquine  [18]  are  associated  with  variable  injuries  to  the  cochlear
sensory hair cells and a decrease in neuronal population and supporting structures as well as atrophy of
stria vascularis resulting in SNHL. This might be reversible if appropriate treatment with corticosteroids
in addition to cessation of the drugs is initiated [18, 19].
Takatsu M, et  al.  [2]  showed that  the plasma concentration of interleukin-6 (IL-6),  matrix metalloproteinases-3
(MMP-3), MMP-9 and tumor necrosis factor alpha (TNF-α) were increased in RA patients with accompanying SNHL;
however  the  results  were  only  significant  for  MMP-3  and  IL-6.  The  authors  concluded  that  the  pro-inflammatory
cytokines (IL-6) and MMPs may contribute to harm inner ear cells by an oxidative process.
Hearing Loss in RA 
Conductive Hearing Loss 
Synovial destruction of IS and IM joints 
Rheumatoid nodule [20] 
Sensorineural Hearing Loss  
Auditory neuropathy  
Destruction of the cochlear hair cells 
Drug-induced  
Mixed Hearing Loss Multifocal involvement of the auditory system [11] 
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Passive  smokers  as  well  as  active  smokers  are  at  higher  risk  of  hearing  impairment.  Nicotine-related
vasoconstriction  and  subsequent  decrease  in  the  oxygen  concentration,  due  to  cigarette  smoking,  can  harm
external hair cells and results in declining cochlear function. This can cause SNHL [12].
On the other hand, there is an increased risk of developing rheumatoid nodules and vasculitis in RA patients
who are smokers leading to increased rate of both CHL and SNHL [4, 20, 22]. Dikici O, et al. [12] in a recent
case-control study of 20 adult patients revealed that there is an inverse relationship between Brinkman Index (=
the number of  packs of  cigarettes smoked per day × the number of  years smoking) and Transiently Evoked
Otoacoustic Emissions (TEOAEs), an objective test to determine cochlear function especially outer hair cells, in
patients  with  RA  [23,  24].  The  authors  suggested  that  the  inner  ear  vascular  system  and  nutrition  may  be
disturbed  as  a  result  of  cigarette  smoking.  Furthermore,  there  is  a  strong  correlation  between  smoking  and
rheumatoid nodules in RA seropositive patients probably due to high production of rheumatoid factor (RF) [25].
We found no literature concerning the relationship between hearing loss and nicotine substitutes e.g. nicotine
gum or patches.
Alcohol
The auditory system can be affected by long-term exposure to alcohol. This may be due to harmful effects of
alcohol on the cochlear function especially outer hair cells which can lead to SNHL [26, 27]. However, we did
not find any evidence or study to indicate that RA patients are at a higher level of risk for hearing impairment by
consuming alcohol.
Noise
Noise can cause a wide spectrum of metabolic and mechanical damages in the cochlea leading to hearing loss.
Noise-induced hearing loss is one of the significant causes of acquired hearing loss which is often preventable
[28, 29]. Noise and other factors that affect hearing in healthy individuals are also likely to affect patients with
RA, even though no studies were found evaluating these subjects specifically in RA patients.
EFFECTS OF CLINICAL AND LABORATORY FACTORS
Different variables, summarized in Table 1, may influence the auditory system in RA patients. However, most of the
previous  studies  showed  controversial  results,  partly  due  to  small  sample  sizes  and  partly  due  to  methodological
differences.  Also,  the use of various clinical  evaluations of RA plus different types of hearing tests intensified this
discordance. Elderly Patients and those with long disease duration, active disease, positive RF and increased laboratory
values of acute phase reactants as well as rheumatoid nodules are more likely to have hearing impairment [2, 10, 12, 30
- 32]. A combination of disease activity indices for instance presence of rheumatoid nodule, swollen and tender joints as
well as morning stiffness has been used by earlier studies while recent studies commonly used disease activity score in
28  joints  (DAS28)  to  evaluate  disease  activity  [4].  Dikici  O,  et  al.  [12]  reported  a  higher  incidence  of  hearing
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impairment in males, while Poorey VK, et al.  [10] mentioned that the incidence of hearing impairment is higher in
female patients compared to males. In addition to the above factors, a study by Ozcan M, et al. [9] revealed that there is
a positive correlation between hearing loss and Steinbrocker functional classification index [33], which is a scoring
system in RA based on the worst joints. It was also shown by Dikici O, et al.  that platelet count is associated with
hearing  impairment,  since  increase  in  platelet  count  and  relative  hyperviscosity  may  lead  to  blood  circulation  and
nutrition disturbances in the inner ear, causing SNHL [12]. In contrast to these findings, results of number of studies
demonstrated that there is no correlation between aging [34], sex [2, 34], rheumatoid nodules [4], DAS28 [4], disease
duration [2, 4, 10, 32, 34] as well as RF [4] and hearing impairment in RA patients.
Table 1. Different variables are associated to the hearing impairment in patients with Rheumatoid Arthritis.  (Data were








CHARACTERISTICS OF HEARING LOSS
Different types of hearing tests are available and described in the previous studies mostly pure tone audiometry and
Otoacoustic Emissions to accurately diagnose hearing loss in RA patients.
Pure Tone Audiometry
Pure tone audiometry is the most frequent test to assess hearing loss, and is performed at frequencies varying
from low pitches 250 Hz to high pitches 8000 Hz. 250 Hz and 500 Hz are low frequencies; 1000 Hz and 2000
Hz  are  middle  frequencies;  and  4000  Hz  and  8000  Hz  are  high  frequencies.  Extended  high  frequency
audiometry,  which tests  very high frequencies ranging from 8,000–16,000 Hz,  can detect  hearing loss at  an
earlier stage; however it is not commonly used [35, 36]. Earlier evaluations revealed that RA patients have a
higher prevalence of hearing loss for all frequencies including low [5], middle [4], high [11] and very high [37].
Transiently Evoked Otoacoustic Emissions
TEOAEs test has been used widely to evaluate cochlear function in pediatric and adult populations, since it is
easily detectable and can be modified according to age and gender. In this technique sounds emitted in response
to acoustic stimuli of very short duration. These sounds are produced by healthy cochlear systems most probably
the outer hair cells, whereas any kind of cochlear dysfunction results in decrease or disappearance of TEOAEs
[23]. Various amounts of decreases have been reported in RA patients. However some of these patients had
normal hearing representing an early stage of hearing impairment [4, 5, 12].
MANAGEMENT
There is no consensus regarding the management of hearing impairment in patients with rheumatoid arthritis. Based
on empirical grounds, treatment with oral steroid plus cessation of ototoxic drugs should be initiated [18, 20, 33, 38].
Under special circumstances, intratympanic application of steroids with optimized dosage may result in better response
(frequencies  over  2000 Hz)  [38].  Limited  data  suggest  using steroid-sparing agents  such as  methotrexate  and TNF
inhibitors  (infliximab),  separately  or  in  combination  with  other  drugs,  that  can  decrease  side  effects  of  long-term
corticosteroids [39, 40]. One study recommended treatment with vasodilators to improve cochlear circulation, when
there  is  a  decrease  in  emission  amplitudes.  Anti-oxidants  for  instance  sodium  salicylate,  vitamin  E  and  N-acetyl
cysteine may play a protective role for the inner ear [12]. Although hearing impairment may present as a subclinical
disease, regular audiometric test and TEOAEs is advisable and can diagnose hearing loss at an early stage [11, 12].
Alternatively, assessment of immunoglobulins, complement and acute phase reagents as well as more specific method
(e.g. Western-blot (WB) for anticochlear autoantibodies) clarifies the pathogenesis of the disease and may be a lead to
earlier diagnosis [41, 42]. When there is a clinical suspicion of serous otitis, radiographic evaluation of affected ear may
be  beneficial  to  diagnose  RA  nodules  [20].  Patients  and  their  families  should  be  aware  of  the  noxious  effects  of
smoking on the inner ear which can deteriorate the condition [12]. As alcohol consumption may deteriorate hearing
impairment,  reduction  or  cessation  of  alcohol  use  is  beneficial  [26,  27].  In  the  CHL  and  MHL  cases,  surgical
30   The Open Rheumatology Journal, 2016, Volume 10 Emamifar et al.
intervention  may be  required  to  repair  the  sound  conduction  mechanism of  the  middle  ear  [9].  Ordinarily,  hearing
impairment in patients with RA can also be managed like other causes of hearing loss in general population. Thus in the
presence of irreversible hearing loss, using various types of hearing aids and implantable devices are helpful [43].
CONCLUSION
Based on our review it can be postulated that patients with RA are at higher risk of hearing impairment compared to
healthy subjects in their course of the disease. In spite of wide diversity regarding published results, it is obvious that
hearing impairment in RA is a multifactorial disease, since it can be affected by environmental factors (e.g. smoking),
and disease characteristics (e.g. rheumatoid nodule) as well as patients characteristic (e.g. age). On the other hand, these
factors may affect each other both directly and indirectly. For instance, aging has a direct effect on the duration of the
disease, and exposure to environmental factors (e.g. noise and acoustic trauma, smoking, etc.) will be increased with
aging of the patients. Furthermore, aging is the most frequent cause of age-related hearing loss (Presbycusis). Another
example of this is the effect of sex on hearing impairment, while RA affects most commonly female gender; hearing
impairment has a higher prevalence in males in comparison with females resulting in counterbalancing each other’s
effects [44, 45]. We think that future research should focus on the different pathologies of hearing impairment more
precisely, since it can be a lead to better treatment options and prevent further morbidities in RA patients. In the future
we are going to conduct a meta-analysis to evaluate the effect of RA on audiological tests to limit the effect of the
sample size on the results. To the best of our knowledge, this is the first review of hearing impairment in RA.
ABBREVIATIONS
CHL = conductive hearing loss
DAS28 = disease activity score in 28 joints





MHL = mixed hearing loss
MMP-3 = matrix metalloproteinases-3
MMP-9 = matrix metalloproteinases-9
NSAIDs = non-steroidal anti-inflammatory drugs
RA = rheumatoid arthritis
RF = rheumatoid factor
SNHL = sensorineural hearing loss
TNF = tumor necrosis factor
TNF-α = tumor necrosis factor alpha
TEOAEs = transiently evoked otoacoustic emissions
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